Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 1807 of 6351
-
Sjögren's drug ianalumab tested for Long-Term safety in 600-Patient trial
Disease control OngoingThe purpose of this study is to measure the long-term safety and tolerability of ianalumab in participants with Sjögren's syndrome who have previously completed treatment from one of two NEPTUNUS 1 year core studies (CVAY736A2301 \[NCT05350072\] or CVAY736A2302 \[NCT05349214\]).
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
New hope for tough cancers: experimental drug ZG006 enters human trials
Disease control Recruiting nowThis is a multi-center, open-label, Phase Ⅰ/Ⅱ clinical study of ZG006 for the treatment of participants with small cell lung cancer or neuroendocrine carcinoma who had no standard treatment available, or were intolerant to standard treatment.
Phase 1/2 • Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Immunotherapy before surgery: a new hope for HPV throat cancer?
Disease control Recruiting nowThis phase II trial tests how well atezolizumab works in treating patients with human papillomavirus (HPV) related oropharyngeal squamous cell carcinoma that is able to be removed with surgery (resectable). Immunotherapy with atezolizumab, may include changes in the body's immune…
Phase 2 • Sponsor: Emory University • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
How many people live with rare epilepsies in spain? a nationwide count aims to find out
Knowledge-focused CompletedThe main aims of this study are to gather information about how many children, teenagers and adults in Spain have been diagnosed with Dravet syndrome and Lennox-Gastaut syndrome as well as to learn about the number of new Dravet syndrome and Lennox-Gastaut syndrome cases in perso…
Sponsor: Takeda • Aim: Knowledge-focused
Last updated Aug 20, 2026 00:00 UTC
-
Donor immune cells join fight against Hard-to-Treat leukemia
Disease control Recruiting nowTo learn if adding a healthy person's natural killer (NK) cells to the combination of Azacitidine and Venetoclax can help to control AML. NK cells are cancer- and infection-fighting immune cells.
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
AI-Powered stethoscope could spot hidden heart problems in the ER
Diagnosis Recruiting nowThe Eko Artificial Intelligence (AI) has primarily been evaluated in the primary care setting. The digital stethoscope records a phonocardiogram of heart sounds of the patient and uses machine learning artificial intelligence to identify if there are abnormalities present (Eko He…
Sponsor: Corewell Health South • Aim: Diagnosis
Last updated Jul 22, 2026 00:00 UTC
-
New hope for advanced cancers: first human trial of ODM-212 begins
Disease control Recruiting nowMulti-site, open-label, first-in-human study with 2 parts (dose escalation and dose expansion) in subjects with selected advanced solid tumours
Phase 1/2 • Sponsor: Orion Corporation, Orion Pharma • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New pill shows promise against tough cancers in early trial
Disease control Recruiting nowThis is a multi-center, first-in-human, open label, dose escalation (Part A) and expansion (Part B) Phase 1 study in subjects with advanced solid tumors and in subjects with solid tumors with selected genetic alterations that are either direct (YES1 amplification) or dependent (H…
Phase 1 • Sponsor: Nuvectis Pharma, Inc. • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New combo therapy targets tough leukemia mutations
Disease control Recruiting nowThe researchers are doing this study to see if the combination of gilteritinib with ivosidenib or enasidenib is a safe and effective treatment for people with relapsed/refractory AML with FLT3/IDH1 or FLT3/IDH2 gene mutations. The researchers will also look for the highest dose o…
Phase 1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Tailored radiation blasts lung tumors faster in new trial
Disease control Recruiting nowThe purpose of this study is to examine the use of hypofractionated accelerated radiation therapy (HART) to treat locally advanced lung cancer. Depending on the location and size of the tumor.
Phase 1 • Sponsor: Stanford University • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Phage power: can viruses beat superbugs in the gut?
Disease control PausedThe study is a first-in-human Phase 1/2a randomized, double-blind, placebo-controlled trial to assess the clinical safety and efficacy of VRELysin in healthy and VRE-colonized adults.
Phase 1/2 • Sponsor: Intralytix, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Can a traditional chinese herb pill help Lung-Heart patients breathe easier?
Disease control Recruiting nowThis study aims to compare the effectiveness and safety of two treatment approaches for patients with severe pulmonary hypertension: standard targeted drug therapy alone, and a combination of standard targeted drugs plus Qishen Yiqi Dropping Pills over 52 weeks of treatment. Pul…
Sponsor: Guangdong Provincial People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New trial tests smarter bladder cancer surgery to save Men's sexual health
Symptom relief Recruiting nowThe purpose of this clinical trial is to determine if prostate-capsule-sparing cystectomy improves functional outcomes without comprising oncologic outcomes in male patients receiving a radical cystectomy. Patients will be randomized to one of two groups: prostate capsule-sparing…
Sponsor: Johns Hopkins University • Aim: Symptom relief
Last updated Jun 27, 2026 07:58 UTC
-
Nerve block may fix COVID smell problems, study says
Symptom relief CompletedChronic olfactory dysfunction, both hyposmia and parosmia, from the COVID-19 pandemic is a growing public health crisis with up to 1.2 million people in the United States affected. Olfactory dysfunction impacts one's quality of life significantly by decreasing the enjoyment of fo…
Phase 2 • Sponsor: Washington University School of Medicine • Aim: Symptom relief
Last updated Jun 27, 2026 07:56 UTC
-
Could a nerve pain drug and exercise ease long COVID fatigue?
Symptom relief Stopped earlyThis is a single-center, prospective, randomized, double-blind (pharmacotherapy), placebo-controlled, and comprehensive rehabilitation phase II clinical trial to determine the usefulness of pregabalin in a new indication (post-COVID chronic fatigue syndrome). Patients will be ra…
Phase 2 • Sponsor: National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo targets tough sarcomas in kids and adults
Disease control Recruiting nowThe purpose of this study is to better understand how safe and effective the drug cabozantinib in combination with high-dose ifosfamide is in the treatment of children and adults with relapsed/refractory sarcomas.
Phase 1 • Sponsor: Children's Hospital of Philadelphia • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a shingles shot protect transplant patients? timing may be key.
Vaccine Recruiting nowThis research is designed to determine if the adjuvanted recombinant glycoprotein E (gE) herpes zoster (HZ) vaccine (Shingrix) has acceptable immunogenicity and safety in people who have undergone allogeneic stem cell transplant (allo-SCT). Specifically, it will determine the eff…
Phase 2 • Sponsor: University of Colorado, Denver • Aim: Vaccine
Last updated Jun 27, 2026 09:02 UTC
-
Engineered immune cells take on Hard-to-Treat cancers
Disease control Recruiting nowTo find the recommended dose of TROP2- CAR-NK cells that can be given to participants with advanced forms of solid tumors.
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
One shot, two protections? new study combines e. coli and flu vaccines for seniors
Prevention CompletedThe purpose of this study is to show that high-dose quadrivalent seasonal influenza vaccine (HD QIV) given together with 9-valent extraintestinal pathogenic Escherichia coli vaccine (ExPEC9V) does not induce lower antibody response against each of the 4 influenza vaccine strains,…
Phase 3 • Sponsor: Janssen Research & Development, LLC • Aim: Prevention
Last updated Jun 27, 2026 12:03 UTC
-
Engineered immune cells take on Hard-to-Treat colon cancer
Disease control Recruiting nowThis study aims to determine the safety and best response of treatment with CNA3103 (Leucine-rich repeat-containing G protein-coupled receptor 5 \[LGR5\]-targeted, Autologous Chimeric Antigen Receptor (CAR) -T Cells), for participants with Metastatic Colorectal Cancer. Participa…
Phase 1/2 • Sponsor: Carina Biotech Limited • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC